Siegfried and BioNTech Sign Contract for the Aseptic Fill & Finish of a COVID-19 Vaccine

The Siegfried Group (SIX: SFZN) announces that it has signed a cooperation and supply agreement with Biopharmaceutical New Technologies (BioNTech), a German immunotherapy company, for the large-scale filling and packaging of commercial quantities of BNT162b2, an innovative COVID-19 vaccine candidate. Following successful approval, the vaccine developed by BioNTech in cooperation with Pfizer, a US American pharmaceutical company, will be filled by Siegfried at its Hameln site from mid 2021 onwards.

Siegfried CEO Dr. Wolfgang Wienand: “We are proud to make an important contribution toward combatting the pandemic through this partnership, and we are determined to support BioNTech in the best possible way. As a leading CDMO company with a strong global manufacturing network, Siegfried is in a position to take on technologically demanding tasks at short notice and to quickly build up the necessary capacities.”

The BNT162b2 vaccination, jointly developed by BioNTech and Pfizer, is currently undergoing global pivotal clinical phase 2/3 trials. If the study is successful, it is planned to seek regulatory review in October 2020. For the aseptic filling and packaging ("fill & finish") of the vaccine, Siegfried will invest in a dedicated production line at its Hameln (Germany) site and provide special storage capacity. The first phase of the agreement will end 2022, with the shared intention to expand the cooperation into a strategic partnership between BioNTech and Siegfried.

Marianne Späne, Global Head Business Development & Sales at Siegfried: "We very much look forward toward the cooperation with this pioneer company for biopharmaceuticals. This contract, for which we will make full use of our technical capabilities and high quality standards, represents the first step for us toward a long-term partnership with further potential.”

» Media Relase (PDF)

 

Contact Media
Peter Gehler, Chief Communications Officer
peter.gehler@siegfried.ch
Tel. +41 62 746 11 48
Mob. +41 79 416 41 16

Contact Financial Analysts 
Reto Suter, Chief Financial Officer
reto.suter@siegfried.ch
Tel. +41 62 746 11 35

Siegfried Holding AG
Untere Bruehlstrasse 4
CH-4800 Zofingen
Tel. +41 62 746 11 11


About Siegfried
The Siegfried Group is a global life sciences company with sites in Switzerland, the USA, Malta, China, Germany and France. In 2019, the company achieved sales of 833.5 million Swiss francs and currently employs about 2500 people at nine sites on three continents. Siegfried Holding AG is publicly listed on SIX Swiss Exchange (SIX: SFZN).

Siegfried is active in manufacturing pharmaceutical APIs (and their intermediates) as well as drug products (tablets, capsules, sterile vials, ampoules, and cartridges) for the pharmaceutical industry and provides development services.

Contact:

Siegfried AG
Peter A. Gehler
Chief Communication Officer
Untere Bruehlstrasse 4
4800 Zofingen
Switzerland

Phone +41 62 746 1148
peter.gehler@siegfried.ch

to the top to top

Can't find the information
you are looking for?
Contact us

Siegfried AG
Untere Bruehlstrasse 4
CH-4800 Zofingen

Phone: +41 62 746 1111
Fax: +41 62 746 1202
info@siegfried.ch

https://comicsnake.com/dc-comics/ myhentai.org https://besthentai.world/ https://magazine-pdf.net/